Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011

CRANBURY, N.J., May 31, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Matthew R. Patterson, President and Acting Chief Executive Officer, will present a corporate overview at the Jefferies 2011 Global Healthcare Conference in New York, NY on Tuesday, June 7 at 12:15 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days. Participants are encouraged to visit the web site 10 minutes prior to the start of the presentation to register, download and install any necessary software.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program Amigal(tm) (migalastat HCl) is in Phase 3 for the treatment of Fabry disease.

FOLD-G

SOURCE Amicus Therapeutics

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.